This content from the 2020 ASCRS Virtual Annual Meeting is only available to ASCRS members. To log in, click the teal "Login" button in the upper right-hand corner of this page.
To assess the vasoconstrictive effect of Brimonidine 0.15% on reducing subconjunctival hemorrhage after suction ring application during Femtosecond laser assisted cataract surgery (FLACS).
This was a masked prospective randomized controlled study. Inclusion criteria included all FLACS cases between June and August 2019. Exclusion criteria included anticoagulation therapy, prior conjunctival surgery, intraop complications, Analyzed Area <25mm2 or >10% difference between postop vs. preop values. All subjects in Control and Study groups underwent baseline images with the Oculus Keratograph M5. Bulbar Redness Score and Analyzed Area were recorded. All operated eyes then received the usual preop eye drops. Subjects in the Study group received an additional drop of Brimonidine 0.15%. All subjects then underwent FLACS. Comparison images were repeated 15 minutes postop in both groups.
Preop Bulbar Redness Score (BRS) (Study=1.62±0.52; Control=1.40±0.34; P=0.07) and Analyzed Area (AA) (Study=28.86±2.86; Control=26.04±2.93; P=0.28) were not statistically significant between Study and Control groups. Postop BRS (Study=1.42±0.44; Control=1.46±0.43; P=0.70) and AA (Study=26.96±2.82; Control=26.40±2.98; P=0.46) were also not statistically significant between the two groups. However, the change in BRS between preop and postop was statistically significantly greater in the control group (0.06±0.43) compared to the study group (-0.12±0.56) (P=0.03). The change in AA in the postop vs. preop (Study=0.40%±3.60%; Control=1.40%±4.30%; P=0.33) was not statistically significant.
Preoperative application of Brimonidine 0.15 % can significantly decrease the severity of subconjunctival hemorrhage in eyes undergoing FLACS.